Right or Left Primary Site of Colorectal Cancer: Outcomes From the Molecular Analysis of the AGITG MAX Trial
Gonzalo Tapia Rico, Timothy Price, Niall Tebbutt, Jennifer Hardingham, Chee Lee, Luke Buizen, Kate Wilson, Val Gebski, Amanda Townsend
CLINICAL COLORECTAL CANCER | CIG MEDIA GROUP, LP | Published : 2019
BACKGROUND: For metastatic colorectal cancer, previous reports have described differences in biology and outcome, including response to biologic agents, based on whether the primary tumor is right- or left-sided. We explored the molecular markers from the AGITG MAX trial. PATIENTS AND METHODS: The AGITG MAX trial was a randomized study comparing capecitabine versus capecitabine + bevacizumab versus capecitabine + bevacizumab + mitomycin C as first-line therapy in advanced colorectal cancer. Patients were classified as having right-sided (caecum to transverse colon) or left-sided (descending colon to rectum) disease according to anatomic location. Baseline characteristics and previously descr..View full abstract
Funding for the molecular testing was received from the Cancer Council South Australian. Additional untied funding was provided by Roche Australia. Statistical analysis was provided by NHMRC CTC.